Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma (PREMIER)

This study has been terminated.
(Terminated by sponsor due to low enrollment; see details below)
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier:
NCT00308087
First received: March 28, 2006
Last updated: December 2, 2013
Last verified: December 2013

March 28, 2006
December 2, 2013
May 2006
June 2009   (final data collection date for primary outcome measure)
Number of Participants With a Complete Response or Unconfirmed Complete Response at Week 8 With Confirmation at Week 12 [ Time Frame: Week 8 (confirmed at Week 12) ] [ Designated as safety issue: No ]
Count of number of participants who responded with a Complete Response (complete disappearance of all detectable clinical and radiological evidence of disease) at week 8 and again clinically and radiologically confirmed at week 12.
Complete response rate for rituximab plus sargramostim measured at 8 weeks confirmed at 12 weeks
Complete list of historical versions of study NCT00308087 on ClinicalTrials.gov Archive Site
  • Summary of Treatment-Emergent Adverse Events (TEAE) [ Time Frame: up to 12 weeks ] [ Designated as safety issue: Yes ]
    Count of the number of participants who experienced treatment emergent adverse events (TEAEs). TEAEs occurred during the time study intervention was being taken occurring on or after Day 1 and no longer than 30 days after the last dose of study medication.
  • Participant Summary of Best Response Across All Visits [ Time Frame: up to 24 months ] [ Designated as safety issue: No ]

    Count of participants' best response within categories defined by the International Working Group (IWG):

    > Complete Response (complete disappearance of detectable clinical and radiological evidence of disease),

    > Complete Response Unconfirmed (unconfirmed complete disappearance),

    > Partial Response (>=50% decrease sum of the product of the greatest diameters in the six largest dominant nodes or nodal masses),

    > Stable Disease (neither response nor disease progression),

    > Progression (new lesion or increase by 50% of previously involved sites from nadir).

  • Kaplan-Meier Estimates of Progression-Free Survival [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Time to event was measured from the date of randomization to the date of first progressive disease (PD) or death.
  • Kaplan-Meier Estimates for Duration of Partial Response or Better to Treatment [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Count of days in which a participant experiences a Partial Response (>=50% decrease sum of the product of the greatest diameters in the six largest dominant nodes or nodal masses) or better. Time to event was measured from the date of response to the date of progressive disease (PD) or death.
  • Summary of Cost Effectiveness [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    A cost-effectiveness analysis from the payer perspective was to be performed. Only direct medical costs for each patient during the study period were to be included for analysis. Costs were to be calculated by multiplying each health care resource unit by the amount reimbursed by a payer. Health care resource utilization units are a way to normalize the quantity of health care provided to each participant so that costs can be compared.
Safety, overall response rates, progression free survival, cost effectiveness at 24 months
Not Provided
Not Provided
 
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma
Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-cell Lymphoma

The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.

On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. As of 29 August 2009, Genzyme assumed responsibility for the close out of the study. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc.

The study was terminated early due to low enrollment; significant changes to the protocol would have been required to keep pace with the changing therapeutic landscape of indolent lymphoma.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Lymphoma, Follicular
  • Drug: Sargramostim (Leukine)
    Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
    Other Names:
    • Sargramostim
    • Leukine
    • Bay86-5326
  • Drug: Rituximab
    Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
  • Active Comparator: Rituximab
    Intervention: Drug: Rituximab
  • Experimental: Rituximab + Sargramostim
    Interventions:
    • Drug: Sargramostim (Leukine)
    • Drug: Rituximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
75
June 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria (abbreviated list):

  • Relapsed follicular B-cell lymphoma
  • One or more previous therapies for non-Hodgkin's
  • At least one measurable tumor by CT scan or MRI
  • Additional criteria to be determined at screening visit

Exclusion Criteria (abbreviated list):

  • Rituximab refractory (less than 6 months from last treatment with rituximab to relapse)
  • Currently receiving treatment for another cancer
  • Infection currently being treated
  • Active Hepatitis B
  • History of HIV infection
  • Pregnant
  • Additional criteria to be determined at screening visit
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT00308087
310421, 91499, PREMIER
Yes
Sanofi ( Genzyme, a Sanofi Company )
Genzyme, a Sanofi Company
Not Provided
Study Director: Medical Monitor Genzyme, a Sanofi Company
Sanofi
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP